CA2709732A1 - Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile - Google Patents

Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile Download PDF

Info

Publication number
CA2709732A1
CA2709732A1 CA2709732A CA2709732A CA2709732A1 CA 2709732 A1 CA2709732 A1 CA 2709732A1 CA 2709732 A CA2709732 A CA 2709732A CA 2709732 A CA2709732 A CA 2709732A CA 2709732 A1 CA2709732 A1 CA 2709732A1
Authority
CA
Canada
Prior art keywords
imiquimod
formulation
lower dosage
dosage strength
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2709732A
Other languages
English (en)
Other versions
CA2709732C (fr
Inventor
Michael T. Nordsiek
Sharon F. Levy
James H. Lee
James H. Kulp
Kodumudi S. Balaji
Tze-Chiang Meng
Jason J. Wu
Valyn S. Bahm
Robert Babilon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Graceway Pharmaceuticals, Llc
Michael T. Nordsiek
Sharon F. Levy
James H. Lee
James H. Kulp
Kodumudi S. Balaji
Tze-Chiang Meng
Jason J. Wu
Valyn S. Bahm
Robert Babilon
Medicis Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graceway Pharmaceuticals, Llc, Michael T. Nordsiek, Sharon F. Levy, James H. Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon, Medicis Pharmaceutical Corporation filed Critical Graceway Pharmaceuticals, Llc
Priority claimed from CA2649893A external-priority patent/CA2649893C/fr
Publication of CA2709732A1 publication Critical patent/CA2709732A1/fr
Application granted granted Critical
Publication of CA2709732C publication Critical patent/CA2709732C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

CA2709732A 2009-01-14 2009-01-15 Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile Active CA2709732C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14473109P 2009-01-14 2009-01-14
US61/144,731 2009-01-14
CA2649893A CA2649893C (fr) 2009-01-14 2009-01-15 Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2649893A Division CA2649893C (fr) 2009-01-14 2009-01-15 Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile

Publications (2)

Publication Number Publication Date
CA2709732A1 true CA2709732A1 (fr) 2009-08-17
CA2709732C CA2709732C (fr) 2018-04-10

Family

ID=42732742

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709732A Active CA2709732C (fr) 2009-01-14 2009-01-15 Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile

Country Status (1)

Country Link
CA (1) CA2709732C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163617A1 (fr) 2010-06-25 2011-12-29 Graceway Pharmaceuticals, Llc Polythérapie par cryochirurgie et imiquimod à faible intensité de dosage pour traiter la kératose sénile

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163617A1 (fr) 2010-06-25 2011-12-29 Graceway Pharmaceuticals, Llc Polythérapie par cryochirurgie et imiquimod à faible intensité de dosage pour traiter la kératose sénile
EP2584900A1 (fr) * 2010-06-25 2013-05-01 Medicis Pharmaceutical Corporation Polythérapie par cryochirurgie et imiquimod à faible intensité de dosage pour traiter la kératose sénile
EP2584900A4 (fr) * 2010-06-25 2014-02-26 Medicis Pharmaceutical Corp Polythérapie par cryochirurgie et imiquimod à faible intensité de dosage pour traiter la kératose sénile
AU2011270724B2 (en) * 2010-06-25 2016-10-06 Medicis Pharmaceutical Corporation Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis

Also Published As

Publication number Publication date
CA2709732C (fr) 2018-04-10

Similar Documents

Publication Publication Date Title
US11318130B2 (en) 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
US11850245B2 (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US20110319811A1 (en) Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
CA2649893C (fr) Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile
CA2709732A1 (fr) Formulations d'imiquimod a faible dose et schema posologique de courte duree permettant de traiter la keratose senile
CA2697978A1 (fr) Formulations d'imiquimod a faible dose et schema posologique de courte duree pour traiter les verrues genitales

Legal Events

Date Code Title Description
EEER Examination request